Evidence in favour
- Participation spans 10 named insiders rather than one filing source.
- The latest qualifying evidence is fresh, dated 08 Sep 2026.
Company insider dossier
Century Therapeutics Inc insider intelligence
IPSC filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
12/100
Concentrated distribution
96/100 confidence- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Latest evidence
- 9 Sep 2026
Investment committee read
Concentrated distribution
Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.
Review exposure and filing contextDecision risks
- Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 1.94 USD
- One-week move
- -8.1%
- Four-week move
- +1.0%
- Fair-value gap
- +8.8%
- Trend signal
- Inactive
- Relative strength
- 4.7
Directional balance
Controlled event mix
0.0%acquisition
- Acquisition events
- 0
- Disposal events
- 14
- Net value
- -$180.4K
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
103 Aug
110 Aug
017 Aug
024 Aug
131 Aug
307 Sep
014 Sep
Named participants
Insider conviction by person
BLACKWELL, KIMBERLYDirector500 events
LEE, HAN MYUNGDirector500 events
MURPHY, MARTIN PATRICKDirector500 events
QUIMI, DAPHNEDirector500 events
RIVA, ALESSANDRODirector500 events
TRUITT, JOSEPHDirector500 events
COWAN, CHADChief Scientific Officer281 events
RUSSOTTI, GREGORYSee Remarks223 events
CARR, DOUGLASSVP Finance & Operations195 events
PFEIFFENBERGER, BRENTDirector, President and CEO195 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable IPSC filing ledger
Showing 1 to 20 of 20.
TRUITT, JOSEPHDirector
AcquisitionOptions and derivatives
148000 sharesStock Option (right to buy)
Not reportedContext evidence
RUSSOTTI, GREGORYSee Remarks
DisposalCommon equity
534 sharesCommon Stock
$1.1KDirectional evidence
CARR, DOUGLASSVP Finance & Operations
DisposalCommon equity
254 sharesCommon Stock
$521Directional evidence
PFEIFFENBERGER, BRENTDirector, President and CEO
DisposalCommon equity
463 sharesCommon Stock
$977Directional evidence
PFEIFFENBERGER, BRENTDirector, President and CEO
DisposalCommon equity
31172 sharesCommon Stock
$59.9KDirectional evidence
CARR, DOUGLASSVP Finance & Operations
DisposalCommon equity
275 sharesCommon Stock
$544Directional evidence
RUSSOTTI, GREGORYSee Remarks
DisposalCommon equity
2584 sharesCommon Stock
$5.8KDirectional evidence
CARR, DOUGLASSVP Finance & Operations
DisposalCommon equity
1654 sharesCommon Stock
$3.7KDirectional evidence
BLACKWELL, KIMBERLYDirector
AcquisitionOptions and derivatives
74000 sharesStock Option (right to buy)
Not reportedContext evidence
LEE, HAN MYUNGDirector
AcquisitionOptions and derivatives
74000 sharesStock Option (right to buy)
Not reportedContext evidence
MURPHY, MARTIN PATRICKDirector
AcquisitionOptions and derivatives
74000 sharesStock Option (right to buy)
Not reportedContext evidence
QUIMI, DAPHNEDirector
AcquisitionOptions and derivatives
74000 sharesStock Option (right to buy)
Not reportedContext evidence
RIVA, ALESSANDRODirector
AcquisitionOptions and derivatives
74000 sharesStock Option (right to buy)
Not reportedContext evidence
PFEIFFENBERGER, BRENTDirector, President and CEO
DisposalCommon equity
13849 sharesCommon Stock
$31.0KDirectional evidence
COWAN, CHADChief Scientific Officer
DisposalCommon equity
358 sharesCommon Stock
$802Directional evidence
RUSSOTTI, GREGORYSee Remarks
DisposalCommon equity
524 sharesCommon Stock
$1.1KDirectional evidence
CARR, DOUGLASSVP Finance & Operations
DisposalCommon equity
249 sharesCommon Stock
$526Directional evidence
PFEIFFENBERGER, BRENTDirector, President and CEO
DisposalCommon equity
463 sharesCommon Stock
$986Directional evidence
PFEIFFENBERGER, BRENTDirector, President and CEO
DisposalCommon equity
31172 sharesCommon Stock
$72.9KDirectional evidence
CARR, DOUGLASSVP Finance & Operations
DisposalCommon equity
264 sharesCommon Stock
$618Directional evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.